Karen Cashmere - ZyVersa Therapeutics Chief Officer
| ZVSA Stock | 1.13 0.01 0.88% |
Insider
Karen Cashmere is Chief Officer of ZyVersa Therapeutics
| Age | 72 |
| Address | 2200 N. Commerce Parkway, Weston, FL, United States, 33326 |
| Phone | 754 231 1688 |
| Web | https://www.zyversa.com |
ZyVersa Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2492) % which means that it has lost $0.2492 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5223) %, meaning that it created substantial loss on money invested by shareholders. ZyVersa Therapeutics' management efficiency ratios could be used to measure how well ZyVersa Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -29.78. The current year's Return On Capital Employed is expected to grow to -1.15. At present, ZyVersa Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 36.2 M, whereas Net Tangible Assets are forecasted to decline to (11.6 M).Similar Executives
| Found 14 records | INSIDER Age | ||
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Donald Picker | Cns Pharmaceuticals | 78 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Gabriel BA | Immix Biopharma | 37 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| MBA MD | Immix Biopharma | 49 | |
| Todd MD | Hepion Pharmaceuticals | 55 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| DSc MSE | Immix Biopharma | 75 | |
| JD MBA | Immix Biopharma | N/A | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Nandan BS | Immix Biopharma | 62 | |
Management Performance
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.25 |
ZyVersa Therapeutics Leadership Team
Elected by the shareholders, the ZyVersa Therapeutics' board of directors comprises two types of representatives: ZyVersa Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ZyVersa. The board's role is to monitor ZyVersa Therapeutics' management team and ensure that shareholders' interests are well served. ZyVersa Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ZyVersa Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Wolfe, CFO Secretary | ||
| LaBella MS, Chief RD | ||
| Melda Oconnell, Senior Development | ||
| Pablo MD, Chief Board | ||
| MD FACC, Senior Officer | ||
| Stephen Glover, Chairman, CoFounder | ||
| Karen Cashmere, Chief Officer |
ZyVersa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ZyVersa Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | (480.08 K) | ||||
| Shares Outstanding | 2.34 M | ||||
| Shares Owned By Insiders | 0.61 % | ||||
| Shares Owned By Institutions | 4.47 % | ||||
| Number Of Shares Shorted | 45.48 K | ||||
| Price To Book | 0.38 X | ||||
| EBITDA | (107.74 M) | ||||
| Net Income | (98.3 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 491.97 | Return On Assets (0.25) | Return On Equity (1.52) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.